Thomas Fabian

CFO Nobel Biocare

Zurich, Zurich, Switzerland

About

Finance leader with more than 18 years experience in leading positions across all Finance functions (Accounting, Compliance, Tax, FP&A, M&A), mainly in the MedTech industry. Extensive experience in post merger & acquisition integration. High focus on delivering results through collaborative leadership, involving all stakeholders and giving broad ownership to team members fostering their personal development. Strong track record of business partnering and achieving financial targets.

Experience

  • CFO at Nobel Biocare, Envista Holding Corporation, a Danaher spin-off
    Jul 2020 - Present · 6 yrs

  • Senior Finance Direct at Nobel Biocare, Envista Holding Corporation, aDanaher spin-off
    Jan 2019 - Jul 2020 · 1 yr 7 mos

    Financial leadership of three business units with $800M revenue (full P&L ownership). • Set-up new business unit structure, implementing scorecards driving operational and product launch excellence. • Finance lead in due diligence, resulting in acquisition of key supplier in fastest growing business unit, incl. post acquisition integration. • Achieved significant cost reductions.

  • Nobel Biocare, Danaher Corporation (Full-time · 3 yrs 10 mos)
    • Global Head of Controlling
      Jan 2018 - Dec 2018 · 1 yr

      Responsible for Forecasting/Budgeting of NBS, being interface to Danaher Finance team. Leadership of Regional Commercial Finance leaders, Consolidation-, Accounting-, Tax- and Compliance teams. Business partner to several of the Executive Leadership team members of Nobel. • Led outsourcing of transactional accounting shared service centers (AP/AR) in Europe • Implemented HFM - new consolidation system for actuals/forecast/budget • Introduced new lease accounting standard (ASC 842) • Implemented Transfer pricing adjustment process (recognized at DHR CFO conference as best in class)

    • Head of Corporate Controlling
      Mar 2015 - Dec 2017 · 2 yrs 10 mos

      Following the acquisition of Nobel Biocare from Danaher, established all required Accounting-, Tax-, Danaher House of Controls- and FP&A processes. • Implemented Financial Forecast and tax reporting process for P&L/Balance Sheet (40+ entities) • Introduced Danaher House of Controls (SOX, Balance Sheet Reviews, CSAQ, DOA) • Opening Balance Sheet for $2bn Nobel acquisition • Implemented new revenue recognition standard (ASC 606) • Drove tax and accounting efficiencies: reduction Swiss legal entities from 5 to 1, formed accounting shared service centers across EU

  • Beckman Coulter Diagnostics, DANAHER Corporation (5 yrs 7 mos)
    • Regional Controller Emerging Markets
      Nov 2012 - Mar 2015 · 2 yrs 5 mos

      Finance Leadership as business partner working closely with the Commercial VP to drive improvements of the Danaher Core Value Drivers, amongst them being Core Revenue Growth, Operating Margin Expansion, DSO and DPO. Besides driving compliance for all internal and external requirements (US GAAP, Stat and tax accounts, FCPA, DHR House of Controls). • Project lead for the integration of the acquired IRIS business ($30M revenue) in EMEAI • Integration of acquired Dry-Flow Cytometry business into the Indian Finance Operation • De-centralization of Russia accounting to DHR shared-service center

    • Financial Planning Manager
      Sep 2009 - Jun 2013 · 3 yrs 10 mos

  • Head of Controlling and Business Support at Olympus Life Science
    May 2008 - Aug 2009 · 1 yr 4 mos